Literature DB >> 20204541

Recurrent differentiation syndrome or septic shock? Unresolved dilemma in a patient with acute promyelocytic leukemia.

Ramzi Jeddi1, Hela Ghédira, Ramzi Ben Amor, Samia Menif, Zaher Belhadjali, Balkis Meddeb.   

Abstract

Differentiation syndrome (DS) is a life-threatening complication observed in patients with acute promyelocytic leukemia (APL) receiving induction therapy with all-trans-retinoic acid (ATRA). A bimodal incidence of DS has been observed, with a majority of cases occurring during the first week of ATRA treatment ("early" DS), but a substantial number of cases occurring during the third or even fourth week of ATRA treatment ("late" DS). However, to our knowledge occurrence of both early and late DS in the same patient has not been reported. We report an APL patient treated with the AIDA regimen, who experienced both early and late DS, a situation where differential diagnosis was difficult.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20204541     DOI: 10.1007/s12032-010-9462-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  9 in total

1.  Radiologic features of all-trans-retinoic acid syndrome.

Authors:  Jung Im Jung; Jung Eun Choi; Seong Tai Hahn; Chang Ki Min; Chun Choo Kim; Seog Hee Park
Journal:  AJR Am J Roentgenol       Date:  2002-02       Impact factor: 3.959

2.  The "retinoic acid syndrome" in acute promyelocytic leukemia.

Authors:  S R Frankel; A Eardley; G Lauwers; M Weiss; R P Warrell
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

3.  Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.

Authors:  M S Tallman; J W Andersen; C A Schiffer; F R Appelbaum; J H Feusner; A Ogden; L Shepherd; J M Rowe; C François; R S Larson; P H Wiernik
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

4.  Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.

Authors:  Miguel A Sanz; Guillermo Martín; Marcos González; Angel León; Chelo Rayón; Concha Rivas; Dolors Colomer; Elena Amutio; Francisco J Capote; Gustavo A Milone; Javier De La Serna; José Román; Eva Barragán; Juan Bergua; Lourdes Escoda; Ricardo Parody; Silvia Negri; María J Calasanz; Pascual Bolufer
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

5.  Prognostic factors of non-HIV immunocompromised patients with pulmonary infiltrates.

Authors:  Ana Rañó; Carlos Agustí; Natividad Benito; Montserrat Rovira; Joaquim Angrill; Tomás Pumarola; Antoni Torres
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

6.  Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.

Authors:  Pau Montesinos; Juan M Bergua; Edo Vellenga; Chelo Rayón; Ricardo Parody; Javier de la Serna; Angel León; Jordi Esteve; Gustavo Milone; Guillermo Debén; Concha Rivas; Marcos González; Mar Tormo; Joaquín Díaz-Mediavilla; Jose D González; Silvia Negri; Elena Amutio; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Blood       Date:  2008-10-22       Impact factor: 22.113

7.  Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin.

Authors:  Massimo Breccia; Roberto Latagliata; Ida Carmosino; Laura Cannella; Daniela Diverio; Anna Guarini; Maria Stefania De Propris; Maria Concetta Petti; Giuseppe Avvisati; Giuseppe Cimino; Franco Mandelli; Francesco Lo-Coco
Journal:  Haematologica       Date:  2008-10-22       Impact factor: 9.941

8.  Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

Authors:  S De Botton; H Dombret; M Sanz; J S Miguel; D Caillot; R Zittoun; M Gardembas; A Stamatoulas; E Condé; A Guerci; C Gardin; K Geiser; D C Makhoul; O Reman; J de la Serna; F Lefrere; C Chomienne; C Chastang; L Degos; P Fenaux
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

Review 9.  Is steroid therapy ever of benefit to patients in the intensive care unit going into septic shock.

Authors:  Lydia Richardson; Steven Hunter
Journal:  Interact Cardiovasc Thorac Surg       Date:  2008-07-21
  9 in total
  1 in total

1.  Infections in pediatric acute promyelocytic leukemia: from the Canadian infections in acute myeloid leukemia research group.

Authors:  Sonia Cellot; Donna Johnston; David Dix; Marie-Chantal Ethier; Biljana Gillmeister; David Mitchell; Rochelle Yanofsky; Victor Lewis; Carol Portwine; Victoria Price; Shayna Zelcer; Mariana Silva; Lynette Bowes; Bruno Michon; Kent Stobart; Josee Brossard; Joseph Beyene; Lillian Sung
Journal:  BMC Cancer       Date:  2013-06-04       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.